Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof across all patient-relevant parameters, including patient satisfaction with treatment efficacy, formulation elegance, ease of application, impact on daily life and preference for tapinarof versus prior psoriasis therapies. These results were presented by Dermavant Sciences during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, HI. 

“As a clinician, it’s paramount that my patients are satisfied with their treatment, as research shows that patients who are satisfied with their treatment are more likely to continue treatment, which may improve treatment efficacy. I am encouraged by these results with tapinarof showing consistent patient satisfaction, which has often been difficult to achieve with current psoriasis treatments, including steroidal topicals,” said Jerry Bagel, MD, MS, director of the Psoriasis Treatment Center of New Jersey and Eczema Treatment Center of New Jersey in East Windsor, a member of the National Psoriasis Foundation board of directors, and lead author of this publication. “Building on previous PSOARING 3 results, these findings demonstrate that tapinarof, subject to FDA approval, has the potential to be a long-awaited new treatment option to improve the care of patients suffering from this debilitating, chronic condition.” 

Responses to the questionnaire, which were assessed at study completion (week 40 or early termination), demonstrated consistent high rates of satisfaction across all evaluated parameters. Of the 78.5% (599/763) of patients from PSOARING 3 who completed the survey:

• Patients preferred tapinarof to prior topical treatments with 81.7% considering it more effective.
• 85.8% either strongly agreed or agreed they could easily manage their psoriasis with tapinarof.  
• 82.5% expressed that they would use tapinarof again or continue using it if available.

“As a team that is driven by a passion for helping patients, we are delighted to present findings for patient satisfaction with tapinarof from PSOARING 3 during the 2022 Winter Clinical Dermatology Conference, highlighting our continued commitment to addressing unmet needs for patients with inflammatory skin conditions,” said Philip M. Brown, MD, JD, Chief Medical Officer of Dermavant. “We know that patients with plaque psoriasis and their physicians are looking for non-steroidal topical treatment options, and we hope to bring long-overdue innovation to this community.” 

In August 2021, the FDA accepted a New Drug Application for tapinarof for the treatment of plaque psoriasis in adult patients and assigned a Prescription Drug User Fee Act target action date in Q2 2022.